Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.9124 ^USD	-2.51%		+3.68%	+4.87%

May. 13	European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	MT
May. 10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT

Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares.

May 01, 2024 at 07:10 am EDT

Amarin Corporation plc (NasdaqGM:AMRN) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its ADSs. The implementation of the repurchase program is conditional upon shareholder and UK court approval.

Latest news about Amarin Corporation plc

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	May. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	May. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	May. 07	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	May. 01	MT
Transcript : Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024	May. 01
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M	May. 01	MT
Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares.	May. 01	CI
Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Amarin Corporation plc authorizes a Buyback Plan.	Apr. 30	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 06	CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	Mar. 20	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	Mar. 18	MT

Chart Amarin Corporation plc

Duration

Period

More charts

Company Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Amarin Corporation plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.9124 USD

Average target price

1 USD

Spread / Average Target

+9.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AMARIN CORPORATION PLC	+4.87%	385M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs